Gastrointestinal Cancer, Undernutrition
Conditions
Keywords
undernutrition, gastrointestinal cancer, skeletal muscle, energy metabolism
Brief summary
Undernutrition associated with cancer, or cancer cachexia results from a deterioration of the energy balance that leads to a gradual mobilization of energy reserves in the body and to increasing deterioration of the nutritional status of patients. This will thus significantly reduce quality of life and survival of patients with a lower tolerance to cancer treatments. Despite undeniable progress in knowledge, many pathophysiological mechanisms remain few or not explored, which could explain that there is still no satisfactory therapeutic solution to halt the gradual deterioration of the nutritional status of patients. In this sense, apart from preclinical data obtained in animal models, there is currently no clinical study on the functioning of skeletal muscle energy metabolism in undernourished patients suffering of cancer.
Interventions
OTHERSamples
Blood samples, muscle biopsy and sample of hair
Sponsors
Inserm U1069 - Team Nutrition, Growth and Cancer
University Hospital, Tours
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Case group selection criteria: Inclusion Criteria: * 18 years ≤ Age ≤ 80 years * Colorectal pancreatic cancer * Undernutrition related to cancer (weight loss \> 5% weight in one month or 10% in 6 months) * Indication to systemic chemotherapy * Indication to the development of an implantable port * Life expectancy ≥ 3 months * WHO General Status ≤ 2 * Patients affiliated to social security scheme * Informed consent signed by the patient
Exclusion criteria
* Pregnant or breastfeeding women * Unbalanced Diabetes * Systemic corticosteroid treatment * Any severe uncontrolled medical condition * Alopecia Control group selection criteria: Inclusion Criteria: * 18 years ≤ Age ≤ 80 years * Colorectal pancreatic cancer * Indication adjuvant chemotherapy * Indication to the development of an implantable port * Life expectancy ≥ 3 months * WHO General Status ≤ 2 * Patients affiliated to social security scheme * Informed consent signed by the patient
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of muscle mitochondrial bioenergetics | An average of one week | Measurement of muscle mitochondrial bioenergetics by high resolution oxygraphy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quantification of muscle lipid droplets | An average of one week | Quantification of muscle lipid droplets by electron microscopy |
| Analysis of the expression of target genes and proteins | An average of one week | Analysis of the expression of target genes and proteins involved in 1/ mitochondrial metabolism 2/ lipid metabolism 3/ the regulation of energy metabolism and 4/ muscle proteolysis by RTqPCR with SYBR Green and by Western Blot |
| Determination of body composition (fat mass / lean mass) | Within 4 weeks before inclusion | Determination of body composition ( fat mass / lean mass ) by an imaging method scannographic |
| Determining the isotopic composition of nitrogen hair | An average of one week | Determining the isotopic composition of nitrogen hair spectrometry . |
Countries
France
Outcome results
None listed